Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  McClure, Janela ^a   Lovelace, Erica S ^a   Elahi, Shokrollah ^c   Maurice, Nicholas J ^b   Wagoner, Jessica ^a   Dragavon, Joan ^a   Mittler, John E ^a   Kraft, Zane ^c   Stamatatos, Leonidis ^a,c   Horton, Helen ^c   de Rosa, Stephen C ^a,b   Coombs, Robert W ^a   Polyak, Stephen J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Viral Vaccines Program Seattle Biomed   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; HLA DR ANTIGEN; KI 67 ANTIGEN; SILIBININ;

ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CD19+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL PROTECTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; NECROSIS; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS INHIBITION;

ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; HELA CELLS; HIV-1; HUMANS; SILYMARIN; VIRUS REPLICATION;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; SILYBUM MARIANUM;

EID: 84864352463     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041832     Document Type: Article

References (46)

1. d'Ettorre G, Paiardini M, Ceccarelli G, Silvestri G, Vullo V, (2011) HIV-associated immune activation: from bench to bedside. AIDS research and human retroviruses 27: 355-364.
2. Haas A, Zimmermann K, Oxenius A, (2011) Antigen-Dependent and-Independent Mechanisms of T and B Cell Hyperactivation during Chronic Hiv-1 Infection. Journal of virology.
3. Roe B, Hall WW, (2008) Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus. Expert Rev Mol Med 10: e30.
4. Operskalski EA, Kovacs A, (2011) HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Current HIV/AIDS reports 8: 12-22.
5. Deming P, McNicholl IR, (2011) Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 31: 357-368.
6. Kim AY, Chung RT, (2009) Coinfection with HIV-1 and HCV-a one-two punch. Gastroenterology 137: 795-814.
7. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, et al. (2001) Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33: 562-569.
8. Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, et al. (2007) Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 21: 2209-2216.
9. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, et al. (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30: 1054-1058.
10. Macias J, Berenguer J, Japon MA, Giron JA, Rivero A, et al. (2009) Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 50: 1056-1063.
11. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, et al. (2008) Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 47: 605-612.
12. Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, et al. (2002) Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 97: 2391-2397.
13. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, et al. (2007) Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology 132: 1925-1936.
14. Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, et al. (2010) Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A 107: 5995-5999.
15. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB, (2006) Anticancer potential of silymarin: from bench to bed side. Anticancer Res 26: 4457-4498.
16. Gazak R, Walterova D, Kren V, (2007) Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 14: 315-338.
17. Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, et al. (2010) Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology 138: 671-681 681 e671-672.
18. Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, et al. (2010) Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 51: 1912-1921.
19. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, et al. (2010) Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. Gastroenterology 138: 1112-1122.
20. Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, et al. (2011) Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One 6: e16464.
21. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, et al. (2008) Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 135: 1561-1567.
22. Payer BA, Reiberger T, Rutter K, Beinhardt S, Staettermayer AF, et al. (2010) Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J Clin Virol 49: 131-133.
23. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
24. Vodicka MA, Goh WC, Wu LI, Rogel ME, Bartz SR, et al. (1997) Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 233: 193-198.
25. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, et al. (1965) Continuous Culture of Human Lymphoblasts from Peripheral Blood of a Child with Acute Leukemia. Cancer 18: 522-529.
26. Wain-Hobson S, Vartanian JP, Henry M, Chenciner N, Cheynier R, et al. (1991) LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. Science 252: 961-965.
27. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, et al. (1986) The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233: 215-219.
28. Koup RA, Ho DD, Poli G, Fauci AS, (2001) Isolation and quantitation of HIV in peripheral blood. Current protocols in immunology/edited by John E Coligan [et al] Chapter 12: Unit 12 12.
29. Reed LJ, Muench H, (1938) A simple method of estimating fifty percent endpoints. The American Journal of Hygiene 27: 493-497.
30. Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J, (2002) HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS research and human retroviruses 18: 567-576.
31. Poss M, Overbaugh J, (1999) Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. Journal of virology 73: 5255-5264.
32. Lovelace E, Xu H, Blish CA, Strong R, Overbaugh J, (2011) The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization. Virology 421: 235-244.
33. Blish CA, Jalalian-Lechak Z, Rainwater S, Nguyen MA, Dogan OC, et al. (2009) Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. Journal of virology 83: 7783-7788.
34. Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J, (2007) HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 21: 693-702.
35. Rainwater SM, Wu X, Nduati R, Nedellec R, Mosier D, et al. (2007) Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr HIV Res 5: 189-197.
36. McClure J, van't Wout AB, Tran T, Mittler JE, (2007) Granulocyte-monocyte colony-stimulating factor upregulates HIV-1 replication in monocyte-derived macrophages cultured at low density. Journal of acquired immune deficiency syndromes 44: 254-261.
37. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R, (2002) Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene 21: 1759-1767.
38. Crouch SP, Kozlowski R, Slater KJ, Fletcher J, (1993) The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. Journal of immunological methods 160: 81-88.
39. Polyak SJ, Morishima C, Hawke R, (2008) Antiviral effects of silymarin against hepatitis C: the jury is still out. Hepatology 48: 345-346.
40. Gibson RM, Arts EJ, (2012) Past, Present, and Future of Entry Inhibitors as HIV Microbicides. Current HIV research 10: 19-26.
41. Permanyer M, Ballana E, Este JA, (2010) Endocytosis of HIV: anything goes. Trends in microbiology 18: 543-551.
42. von Kleist L, Stahlschmidt W, Bulut H, Gromova K, Puchkov D, et al. (2011) Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell 146: 471-484.
43. Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, Ferenci P, (2011) Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. Journal of hepatology 54: 591-592 author reply 592-593.
44. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T, (2010) Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol.
45. Gong G, Waris G, Tanveer R, Siddiqui A, (2001) Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 98: 9599-9604.
46. Cossarizza A, Troiano L, Mussini C, (2002) Mitochondria and HIV infection: the first decade. J Biol Regul Homeost Agents 16: 18-24.